|  HOME   |  Login   |  회원가입   |  사이트맵   |  Contact Us
인사말   /  조직도   /  임원진   /  위원회   /  학회 회칙
투고규정
학회지 검색
학회 소식지
학회지 검색 -
Journal of Multiple Sclerosis 7(1):9-13, 2016
Neutralizing Antibodies in Korean Multiple Sclerosis Patients Treated with Interferon-Beta: Preliminary Study
Jae-Won Hyun, MD, Byungsoo Kong, PhD, AeRan Joung, RN, In Hye Jeong, MD, Su-Hyun Kim, MD,
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea
Background: Patients treated with interferon-beta (IFN-β) can develop neutralizing antibodies (NAB) against IFN-β, which negatively affect its therapeutic responses. We aimed to investigate prevalence of NAB and to evaluate the impact of NAB on the treatment response of IFN-β in Korean patients with multiple sclerosis (MS). Methods: This was a single center, retrospective study of MS patients treated with subcutaneous IFN-β-1a and IFN-β-1b in Korea. Patients with MS who were treated with IFN-β at least for 6 months were enrolled. Sera, which were not influenced by acute treatment for MS, were tested for NAB using the luciferase reporter gene assay. Results: A total of 96 MS patients were enrolled. NAB were found in 28 (29%) patients at the single test; 23 of 66 (35%) patients treated with subcutaneous IFN-β-1b and 5 of 30 (17%) patients treated with subcutaneous IFN-β-1a. The frequency of NAB positivity was highest (n=18, 39%) in patients treated with IFN-β for 12 to 24 months. Until now, 20 of 28 patients with NAB were tested at two different time points to confirm the persistent positivity of NAB. Of 20 patients with NAB at the single test, 11 patients showed persistent positivity of NAB and 8 of them (73%) revealed disease activity before and after 6 months of NAB positivity. In contrast, 3 of 9 patients (33%) who showed transient positivity of NAB showed disease activity. Conclusions: The current study is ongoing to confirm the clinical implication of persistent positivity and titers of NAB in the multi-center cohort.

Journal of Multiple Sclerosis
7(1):9-13, 2016
KEY WORDS : Multiple sclerosis, Neutralizing antibody, Disease modifying treatment